Mast Cells May Be Fueling Your Endometriosis Inflammation

Endometriosis symptoms can keep flaring even when you’re doing “all the right things.” You might be on hormones, you might have had the best possible surgery, you might eat carefully, rest when you can—and still, your pelvis feels angry and unpredictable. That experience is real, and it’s one reason researchers are now asking a different question: what keeps endometriosis inflamed?

One emerging piece of the puzzle is the immune system—especially mast cells, a type of immune cell best known for allergies, but also involved in inflammation, nerve irritation, fibrosis/scarring, and pain signaling. Recent evidence suggests endometriosis lesions can be a particularly “mast-cell-friendly” environment, and estrogen may amplify parts of that immune loop. This doesn’t give you a brand-new treatment to start tomorrow—but it can help you make sense of why symptoms can be stubborn, why “just lower estrogen” isn’t a complete strategy, and what future (and current off-label) options might be worth discussing.

What are mast cells—and why should you care?

Mast cells live in tissues throughout the body. When activated, they can release many chemical messengers (often called “mediators”), including histamine, cytokines, and enzymes. You don’t need to memorize those—what matters is what they can do in the real world:

They can contribute to:

• Inflammation that lingers, even when the original trigger isn’t obvious
• Irritation of nearby nerves, which can worsen pain sensitivity over time
• Swelling and tissue remodeling, which may tie into adhesions and fibrosis
• “Flare-type” symptoms, where things spike around certain triggers (hormonal shifts, stress, illness, foods, environmental exposures) in some people

Not everyone with endometriosis has mast-cell–driven symptoms. But if you also deal with allergy-like issues, histamine intolerance symptoms, migraines, IBS-type symptoms, bladder irritation, or episodic “flares,” this pathway may feel especially relevant.

Endometriosis lesions may attract and support mast cells

In human samples, endometriosis lesions (the tissue outside the uterus) showed higher mast cell density than the uterine lining from the same person (matched samples) and than healthy control endometrium. In other words, lesions weren’t just “cells similar to endometrial tissue in the wrong place”—they looked more like an environment that encourages mast cells to show up and stick around.

A key signal in lesions was higher stem cell factor (SCF) compared with matched uterine lining. SCF is important because it supports mast cell growth and survival—think of it as one way tissue can become welcoming to mast cells.

Lesions also showed increased activity of several mast-cell–relevant genes and recruitment signals (including CCL2, among others). You don’t need to remember all of the genes and molecular pathways involved, but the implication is important remember: lesions may actively create a chemical “pull” for mast cells and then help them persist.

Why this matters to you: if lesions are better at sustaining immune activation than the uterus itself, that may help explain why pain can persist even when bleeding is suppressed, why inflammation can feel out of proportion, and why symptoms can be more systemic than many people expect.

Mast cells can “talk” to endometriosis cells—and increase inflammatory signals

Lab experiments add a practical idea: when endometriosis-related cells were exposed to fluid containing mast-cell secretions, those cells produced more IL‑6 and IL‑8—two inflammatory signals often associated with ongoing inflammation and immune cell recruitment.

In plain language: mast cells may not just be “bystanders” sitting in lesions. They may help keep the lesion environment inflamed. That kind of feedback loop can matter for symptoms like pelvic pain, bowel/bladder irritation, and tenderness that feels inflammatory rather than purely cyclical.

One nuanced point: in this lab setup, hormone exposure alone (estrogen/progesterone) didn’t significantly increase baseline inflammatory cytokines from those cells. That doesn’t mean hormones aren’t relevant—it suggests the immune environment (including mast cells) may be a big part of why hormones don’t fully predict or explain the degree of symptoms.

Estrogen may amplify parts of this immune loop (but this is not a “stop estrogen” message)

A mouse endometriosis model adds a clue that estradiol (E2) may intensify some inflammatory signals and mast-cell presence. With estradiol treatment, mice showed:

• Higher levels of certain systemic inflammatory cytokines in blood (including signals like CXCL1, G‑CSF; IL‑6 increased in the estradiol + endometriosis group at a measured time point)
• More mast cell staining in lesions compared with control uterine tissue
• When directly comparing estrogen-treated lesions to untreated lesions, CCL2 was notably higher with estrogen

This supports the idea that estrogen can interact with immune pathways that affect mast cells. But it does not prove that changing estrogen levels in humans will directly reduce mast-cell activity or pain in a predictable way. Mouse models are not great models for endometriosis related disease but are a good start to gain initial insight into interactions like this.

Your practical takeaway: if you’ve felt like “estrogen makes everything worse,” there may be a biological reason that goes beyond bleeding. At the same time, you deserve individualized counseling, because suppressing estrogen has tradeoffs (mood, bone density, sexual function, vasomotor symptoms), and not everyone’s symptoms track the same way.

What does this mean for treatment decisions right now?

This research strengthens the rationale for why some people ask about antihistamines, mast-cell stabilizers, or MCAS-style approaches—but it does not prove they treat endometriosis pain, because this wasn’t a clinical trial measuring symptom improvement.

Still, you can use this information to have a more targeted conversation about symptom patterns and add-on strategies. In real life, mast-cell–targeted approaches are more likely to be considered when:

• Your symptoms include flares that feel allergy-like or inflammatory
• You have overlapping conditions (IBS, migraine, bladder pain syndrome/interstitial cystitis, eczema, asthma/allergies)
• You have endometriosis treatment but still have burning, itching, swelling, reactive GI symptoms, or cyclical “histamine” symptoms

It also helps validate a key point: endometriosis is not only a “gynecologic condition.” It can be whole body and involve immune activation that behaves more like chronic inflammatory illness.

How long would it take to know if a mast-cell–oriented add-on is helping?

Because there isn’t one proven endometriosis protocol here, timelines vary. In practice, if you and your clinician decide to try something low-risk (for example, a non-sedating H1 and H2 antihistamine), you’d usually want a defined trial window (often a few weeks) with tracking—because endometriosis symptoms fluctuate naturally.

If you try anything new, make it measurable: pain scores, bowel symptoms, bladder urgency, sleep, migraines, fatigue, and flare frequency. The goal is not perfection—it’s knowing whether it’s meaningfully improving your quality of life. Otherwise, without knowing this, you can keep stacking treatments until they actually start interacting and making things worse. Then you are at square one and don't know what treatment to stop.

Practical takeaways: questions to ask your doctor

• Could mast-cell activation or histamine sensitivity be contributing to my symptom pattern (flares, GI/bladder symptoms, allergies, migraines)?
• • There are tissue tests and blood tests (e.g. tryptase, histamine metabolites and prostaglandins) that can be used to determine if there are more mast cells than usual around endo implants and how active they may be
• If I’m already using hormonal suppression, what options exist for persistent inflammatory pain (pelvic floor PT, neuropathic pain options, anti-inflammatory strategies, allergy/immunology referral when appropriate)?
• Would a time-limited trial of an antihistamine be reasonable for my symptoms—and how would we judge success?
• If estrogen may worsen immune activation for some people, which hormone options best fit my priorities (pain control, bleeding control, mood, bone health, fertility goals)?
• If I’m considering surgery, how will you address inflammation and pain sensitization afterward (not just lesion removal)?

Reality check: what we still don’t know (and why results vary)

This line of evidence is compelling, but it has boundaries. It shows association and plausible immune loops—not a guaranteed cause of your pain, and not a proven treatment target yet. Further, the basic treatment options (e.g. H1 and H2 blockers) are limited but more robust molecular therapies, like Tyrosine Kinase Inhibitors (e.g. Avapritinib) are coming out as FDA approved therapies.

A few key caveats that affect real-world decisions:

• Human tissue data here came largely from advanced (stage III–IV) disease; earlier-stage disease and different lesion types may behave differently.
• Mouse and lab findings can’t automatically be translated into “this medication will fix symptoms.”
• Mast cells may be one part of your picture, alongside nerve sensitization, pelvic floor dysfunction, adhesions, adenomyosis, IBS, and central pain sensitization or amplification.

If you feel stuck, a useful reframe is: “What are all the drivers of my pain—and which of them are treatable right now?” Mast cells may be one of several levers, not the only one. Nevertheless, most patients with persistent problems never have this possible avenue of help explored.